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Abstract
Introduction Pancreatogenic diabetes after pancreatectomy is of growing importance due to the increasing life expectancy of
pancreatectomized patients. Although reduction of pancreatic volume is thought to affect glucose metabolism, a consistent
relationship has yet to be determined. This study aimed to investigate functional consequences of distal pancreatectomy (DP)
in preoperatively non-diabetic patients.
Methods This study included 61 non-diabetic patients who underwent DP. Clinical data were obtained, and the percent
resected volume (PRV) of each pancreas was determined via multi-detector row computed tomography volumetry.
Results During the follow-up period (median 26 months), 22 patients (36 %) developed new-onset diabetes within a median
onset time of 8 months (range 0.5–42 months) postoperatively. The remaining 39 patients also showed impaired glucose
metabolism. Multivariate analysis identified preoperative hemoglobin A1c≥5.7 % (odds ratio 15.6, p00.001) and PRV>
44 % (odds ratio 11.3, p00.004) as independent risk factors for new-onset diabetes.
Conclusions Key determinants of postoperative glycemic control include preoperative functional reserve of the endocrine
pancreas and the volume reduction of pancreatic parenchyma. Our findings enable reliable preoperative evaluation of the risk
of postoperative diabetes and appropriate postoperative surveillance, which is helpful for early intervention in high risk
patients.
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Introduction
Pancreatogenic diabetes, classified as type 3c by the Amer-
ican Diabetes Association,1 is associated with diseases of
the exocrine pancreas including pancreatitis, benign and
malignant neoplasm, cystic fibrosis, hemochromatosis,
fibrocalculous pancreatopathy, and trauma and pancreatec-
tomy. Among the 8–9 % of the general diabetes population
with type 3c diabetes in Western countries, 2–3 % are those
who underwent pancreatectomy.2,3 Pancreatectomized
patients are at high risk for type 3c diabetes, as well as type
2, because surgery inevitably results in a deficit in the exocrine
and endocrine pancreas, and also can promote the progression
of underlying disease. Due to improved diagnostic modalities
and a more refined understanding of pancreatic neoplasm
pathogenesis, pancreatectomies for benign or low-grade ma-
lignant tumors are more frequent, and the life expectancy of
patients undergoing pancreatectomy has increased in recent
years. As the frequency of pancreatectomy and length of life
expectancy increase, so does the importance of the risk of
pancreatogenic diabetes associated with pancreatic surgery.
Distal pancreatectomy (DP) is the standard procedure used
for removal of lesions in the body and tail of the pancreas.
Long-term disturbances in glucose metabolism are a major
concern after DP because previous studies have found that
postoperative diabetes develops in from 4.8 to 38 % of
patients after DP.4–8 Physiological factors reported to correlate
with postoperative pancreatic endocrine function include pre-
operative fasting plasma glucose (FPG), body mass index
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(BMI), and postoperative complications.9–11 Limitations in
these studies, such as unspecified preoperative diabetic status
of the patients and inconsistent standards used for the diagno-
sis of postoperative diabetes, make it difficult to reliably
identify risk factors for postoperative diabetes.
Although the mass of pancreatic beta cells has been
identified as an important determinant of plasma glucose
levels in rodents, dogs, monkeys, and humans,12–15 to our
knowledge, very few studies have directly investigated the
volume reduction of human pancreatic parenchyma as a risk
factor for diabetes, and no previous study systematically
quantified resection volumes in a population of patients.
To study potential risk factors for new-onset diabetes in
preoperatively non-diabetic patients, we sought to reliably
quantify the volume reduction of human pancreatic paren-
chyma and to determine its longitudinal metabolic conse-
quences following DP using multi-detector row computed
tomography (MDCT) imaging volumetry.
Methods
Patients
A series of 98 consecutive patients who underwent DP at
our institution between January 2005 and December 2011
was originally chosen from our prospectively maintained
clinical database for this retrospective study. Data from 37
(38 %) of these candidates were excluded due to preopera-
tive diabetes, as defined either by the WHO criteria of
FPG≥126 mg/dl detected on two or more separate days, or
this abnormal FPG level detected once and plasma glucose≥
200 mg/dl measured 2 h after a 75-g glucose drink, or based
on their treatment with oral anti-diabetic agents or insulin.
The final study population consisted of 61 non-diabetic
patients who had undergone DP.
Clinical data on pre- and postoperative patient status
were obtained from existing medical records. Family histo-
ries of type 2 diabetes in first-degree relatives were also
obtained. The preoperative data used for this study had been
recorded within 14 days prior to surgery. Nutritional status
and pancreatic endocrine functions were assessed based on
measurements of body weight, serum albumin, FPG, and
serum hemoglobin A1c (HbA1c). HbA1c values represent
the National Glycohemoglobin Standardization Program
(NGSP) equivalent values (in percent) and in all cases were
converted from previous Japan Diabetes Society standard
substance and measurement methods (JDS HbA1c, in per-
cent) using the following formula: NGSP HbA1c (%)0JDS
HbA1c (%)+0.4 %. The percent resected volume (PRV) of
pancreatic parenchyma, excluding tumor volume, was de-
termined from abdominal MDCT measurements. Patient
data were collected until the time of diagnosis of new-
onset diabetes or tumor recurrence. All 61 patients were
followed up for at least 3 months.
For evaluating postoperative course, we defined and graded
postoperative pancreatic fistula (POPF) using the classification
methods of the International Study Group of Pancreatic
Fistula,16 with POPF grade B or C defined as clinically impor-
tant pancreatic fistula. Postoperative complications were des-
ignated as level I to V based on the Clavien classification.17
Determination of PRV of the Pancreatic Parenchyma
PRVs were determined retrospectively, using preoperative
MDCT images in all patients. Continuous 0.8-mm 64-row
MDCT images were acquired following administration of
intravenous contrast material prior to surgery. MDCT data
were transferred to a computer workstation (Aquarius; Elk,
Osaka, Japan) for measurement of pancreas volume. To
delineate the actual pancreatic resection lines, we compared
preoperative CT with postoperative CT.
Excluding tumors, cystic lesions, any dilation in the
pancreatic duct and bile duct, and vessels, we outlined the
borders of the pancreatic parenchyma and the resection lines
on every CT slice, and we then computed the resected and
remnant areas of pancreatic parenchyma for each slice
(Fig. 1). The volume (in milliliters) of the pancreatic paren-
chyma per slice was calculated as the product of the pan-
creas area (in square millimeters) times the slice thickness
(in millimeters). Resected and remnant volumes of the pan-
creatic parenchyma were computed as the sum of the slice
volumes. PRV was determined using the following formula:
PRV %ð Þ ¼ resected volume of normal pancreas total½ volume
of normal pancreas  100. PRV was calculated in 52 cases.
Fig. 1 MDCT pancreas volumetry. Outlined areas are the remnant
parenchyma (black outline), resected parenchyma (light gray outline),
and tumor (dark grey outline), excluding vessels. The dashed line is the
pancreatic resection line. To determine percent resected volume, the
volume (in milliliters) of the pancreatic parenchyma per slice was
calculated as the product of the pancreas area (in square millimeters)
times the slice thickness (in millimeters)
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In the remaining nine cases, this value could not be measured
accurately because of pancreatic edema or tumors with un-
clear borders that had invaded peri-pancreatic organs.
Definition of Postoperative New-Onset Diabetes
Postoperative new-onset diabetes was diagnosed retrospec-
tively based on the WHO criteria of FPG≥126 mg/dl
detected on two or more separate days, or this abnormal
FPG level detected once and plasma glucose≥200 mg/dl
measured in 2 h after a 75-g glucose drink. The onset day
of diabetes was defined as the latter day on which abnormal
blood test results were detected. In this study population, no
patient was administered anti-diabetic therapy with oral
agents or insulin before the development of diabetes, as
defined by the criteria of this study.
Statistical Analysis
Patient characteristics are reported as means±standard de-
viation (SD), and results are presented as means±standard
error (SE) or, where indicated, medians (range). Categorical
variables are expressed numerically as percentages. For
analyses of repeated measurements of body weight, serum
albumin, FPG, and serum HbA1c prior to and 3, 6, and
12 months after surgery, we used an analysis of variance
(ANOVA) and the Mauchly test, which evaluates the sphe-
ricity assumption. We used the Student’s t test or Mann–
Whitney test for continuous variables and Fisher’s exact test
for categorical variables. A multiple logistic regression anal-
ysis yielding odds ratios and 95 % confidence intervals
(CIs) was used to identify risk factors for postoperative
new-onset diabetes (with p<0.05). The optimal HbA1c
and PRV cutoffs for predicting the occurrence of postoper-
ative new-onset diabetes were estimated using receiver op-
erating characteristic (ROC) curves. All analyses were
performed using JMP 9.0 for Macintosh (SAS Institute
Inc, Cary, NC, USA).
Results
Patients’ Characteristics
Physiological characteristics of the study patients are out-
lined in Table 1. While no patient met the WHO criteria for
diabetes preoperatively, nine had impaired fasting glucose
(IFG), defined as FPG of 110–125 mg/dl. The indications
for DP included pancreatic tumors in 55 of the 61 patients
(90 %, 25 malignant and 30 benign tumors), alcohol-
induced chronic pancreatitis in three patients, autoimmune
pancreatitis mimicking pancreatic cancer in two patients,
and a pseudocyst following acute pancreatitis in one patient.
Three patients had a first-degree family history of type 2
diabetes.
Pancreas Volumetry
MDCT imaging volumetric data showed a wide range of
volumes of whole, remnant, and resected pancreatic paren-
chyma and of tumors in patients with or without new-onset
diabetes (Table 2). While the mean PRV for all 61 cases was
38 % (range 9–85 %), the mean PRV for the new-onset
diabetes group was 49 %, which was significantly higher
than the PRV of 32 % for the non-diabetic group.
Sequential Changes in Diabetic and Nutritional Status After
Surgery
We compared four physiological parameters in new-onset
diabetic versus non-diabetic patients at four time points:
before and 3, 6, and 12 months after surgery. Three months
after surgery, there were significant increases in FPG and
HbA1c in both groups (Table 3). Disturbances in glucose
control occurred within the first 3 months after surgery, and
did not significantly progress after that time in either group.
During the post-DP follow-up period (median 26 months,
range 3–88 months), 22 patients (36 %) developed new-
onset diabetes (median onset time 8 months, range 0.5–
42 months). In most of the 39 patients without new-onset
diabetes, FPG and HbA1c increased significantly during the
follow-up period; however, values remained stable in eight
Table 1 Clinical characteristics of 61 non-diabetic patients who
underwent distal pancreatectomy
Male patients 24 (39)
Age (years) 62±14
BMI (kg/m2) 21.2±3.8
Preoperative HbA1c (%) 5.8±0.41
Preoperative IFG 9 (16)
Preoperative albumin (mg/dl) 4.0±0.64
Preoperative total cholesterol (mg/dl) 182±45
Preoperative pancreatic alpha-amylase (IU/l) 59 (4–264)
Operative time (min) 333±88
Intraoperative blood loss (ml) 427 (5–3524)
Malignancy 25 (41)
Percent resected volume (%) 38±17
POPF ≥ grade B 16 (26)
Postoperative complication ≥ Clavien’s grade II 22 (36)
Postoperative hospital stay (days) 18 (7–58)
Mortality (%) 0
Values are means±SD, medians (range), or n (%)
HbA1c hemoglobin A1c, IFG impaired fasting glucose, FPG fasting
plasma glucose, POPF postoperative pancreatic fistula
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of these 39 patients (change in HbA1c≤0.1 %), and one
patient displayed improvement in glycemic control, as
exhibited by a 0.4 % decrease in HbA1c.
While we observed significant between-group differen-
ces in the changes in FPG (Fig. 2a) (p00.003) and HbA1c
(Fig. 2b) (p<0.001) over time, there were no significant
differences in changes in body weight (Fig. 2c) (p00.36)
or serum albumin (Fig. 2d) (p00.58). Because Mauchly
tests for the sphericity assumption were not significant for
these factors (P00.21, 0.82, 0.28, and 0.30, respectively),
the reported p values are for univariate ANOVA.
Risk Factors for Postoperative New-Onset Diabetes
Univariate analyses identified three statistically significant
risk factors for postoperative new-onset diabetes: preopera-
tive HbA1c≥5.7 %, PRV>44 %, and age (Table 4). Multi-
variate logistic regression analysis also identified HbA1c≥
5.7 % [odds ratio 15.6 (95 % CI 2.80–147), p00.001] and
PRV>44 % [odds ratio 11.3 (95% CI 2.12–92.1), p00.004]
as independent risk factors for postoperative new-onset
diabetes (Table 5). Regarding family history, one of three
patients with first-degree family history of type 2 diabetes,
of whom PRV was 85 %, developed new-onset diabetes at
2 months after surgery. We assessed the sensitivity and
specificity of the HbA1c and PRV parameters using the
ROC curves. The areas under the ROC curves were 0.831
for HbA1c and 0.793 for PRV. Using these curves, HbA1c
of 5.7 % and PRVof 44 % were determined to be the cutoffs
for predicting the occurrence of postoperative diabetes. The
sensitivity, specificity, and positive and negative predictive
values derived from these curves were 0.82, 0.64, 0.56, and
0.86 for HbA1c and 0.75, 0.81, 0.71, and 0.84 for PRV,
respectively.
Discussion
We report here two major findings from this study of
patients who underwent DP. First, in the majority of preop-
eratively non-diabetic patients, DP led to disturbances in
glucose metabolism, and there was a 36 % incidence of
Table 2 CT volumetry in DP patients
All patients New-onset diabetes group No new-onset diabetes group p value
Number of patients with PRV data 52 20 32
Whole normal parenchyma (ml) 56.6 (16.0–128.2) 54.6 (27.0–89.4) 56.6 (16.0–128.2) 0.58
Remnant normal parenchyma (ml) 36.5 (4.4–116.4) 25.1 (4.4–65.8) 38.6 (6.6–116.4) 0.047
Resected normal parenchyma (ml) 18.7 (3.5–57.7) 25.8 (9.9–57.7) 16.5 (3.5–55.3) 0.004
Tumor or cystic lesion (ml) 5.4 (0–543.7) 4.1 (0–38.7) 7.4 (0.2–543.7) 0.11
PRV (%) 38±17 (9–85) 49±15 (20–85) 32±15 (9–59) < 0.001
Values are medians (range) or means±SD (range). p values were obtained using Mann–Whitney U test, except for use of Student’s t test for PRV
CT computed tomography, DP distal pancreatectomy
Table 3 FPG and serum HbA1c before and 3, 6, and 12 months after surgery
All patients
(n061)
p value New-onset diabetes
group (n022)




Before surgery 96±1.9 101±3.8 93±1.9
3 months after surgery 109±2.8 <0.001a 121±5.3 0.008a 102±2.6 0.006a
6 months after surgery 111±4.9 0.29b 133±11.6 0.17b 99±2.4 0.75b
12 months after surgery 114±5.8 0.19b 137±12.2 0.15b 100±3.0 0.55b
HbA1c (%)
Before surgery 5.8±0.05 6.1±0.06 5.6±0.06
3 months after surgery 6.2±0.10 <0.001a 6.7±0.19 0.003a 5.9±0.07 0.002a
6 months after surgery 6.3±0.24 0.73b 7.0±0.51 0.81b 5.9±0.07 1.00b
12 months after surgery 6.4±0.18 0.13b 7.1±0.36 0.49b 5.9±0.06 0.059b
Values are means±SE. Data were analyzed using Student’s paired t test for each group
a Differences compared to values before surgery
b Differences compared to values at 3 months after surgery
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new-onset diabetes postoperatively. Second, in DP patients,
PRV and preoperative HbA1c were independent risk factors
for new-onset diabetes.
Our results enable us to provide evidence-based preoper-
ative counseling and individualized postoperative surveil-
lance. Prior to surgery, we can now offer patients specific
information about their individual risk of postoperative dia-
betes. Postoperatively, appropriate surveillance may detect
the development of impaired glucose metabolism [i.e., im-
paired glucose tolerance (IGT), IFG, and diabetes] at an
early stage and enable early intervention. Intensive glucose
control has been reported to decrease the risks of major
cardiovascular events and death in patients with newly
diagnosed type 2 diabetes.18 Also, in patients with IGT
who are pre-diabetic, the early introduction of anti-diabetic
agents has been reported to diminish the development of
type 2 diabetes.19 The American Diabetes Association rec-
ommends intensive annual monitoring, lifestyle modifica-
tion, and sometimes use of anti-diabetic agents in patients
with IGT, IFG, or HbA1c of 5.7–6.4 % for the prevention
and delay of developing type 2 diabetes.20 Therefore, early
detection and intervention for endocrine insufficiency are
essential for DP patients.
Prior reports have estimated the incidence of new-onset
diabetes after DP at between 9 and 38 % of preoperatively
non-diabetic patients.4,6,8,21 The numerous limitations of
these studies (such as unspecified preoperative diabetic sta-
tus of study patients, inconsistent standards for diagnosis of
postoperative diabetes, and selection of cohorts of patients
with chronic pancreatitis) make it difficult to evaluate the
basis for this wide range of diabetes incidence. In the current
study, the incidence of postoperative new-onset diabetes in
preoperatively non-diabetic patients was 36 %. We attribute
this relatively high measure of incidence to our application
of a definitive classification system and close follow-up.
The results of this study identify PRV>44 % as an
independent risk factor for postoperative new-onset diabetes
in preoperatively non-diabetic DP patients. Although beta
cell mass has previously been reported to be significantly
related to plasma glucose control,14,22,23 volumetric assess-
ments in relation to postoperative endocrine function of the
pancreas remain scarce. Previous studies in large
animals13,15 and humans22 have demonstrated that a 50 %
loss in beta cells elevates plasma glucose. The DP procedure
is often referred to as a “hemi-pancreatectomy,” with an
estimated 50 % reduction in pancreatic volume after tran-
section on the superior mesenteric vein (SMV).9,11 In our
study, the median PRV in 29 patients with transection on the
SMV was 46 %, but we observed a wide range of values in
these cases (PRV from 18 to 67 %), as well as among all
Fig. 2 Changes in parameters before and 3, 6, and 12 months after
surgery: a FPG, b HbA1c, c body weight, and d serum albumin. Values
from patients who developed new-onset diabetes (solid lines) were
compared with non-diabetic patients (dashed lines) using ANOVA,
with evaluation of the sphericity assumption by the Mauchly test.
Postoperatively, there were significant between-group differences in
changes in FPG (p00.003) and HbA1c levels (p<0.001). No signifi-
cant between-group difference in body weight (p00.36) or albumin
(p00.58) was observed
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cases of DP (PRV from 9 to 85 %). Variations in PRV can
also be attributed to differences in the patients’ pancreatic
sizes and shapes, as well as differences in pancreatic tumor
characteristics (i.e., location and the involvement of the
main pancreatic duct that causes atrophy of the distal pan-
creas). Our use of MDCT-based measurements of pancreas
volume resulted in more precise PRV values and thereby
provides evidence that greater resection of pancreatic tissue
increases the incidence of new-onset diabetes in preopera-
tively non-diabetic DP patients. Thus, although pancreatic
resection must be tailored to suit the tumor character (benign
or malignant), location, and extent of tumor invasion, our
data suggest that parenchyma-sparing pancreatectomies
(such as middle pancreatectomy or tumor enucleation) are
more likely to maintain postoperative pancreatic endocrine
function and reduce the risk of diabetes.
In this study, we frequently observed a delay in diabetes
onset in the 22 new-onset diabetics (median time 8 months,
range 0.5–42 months), with only five showing signs of
diabetes within 3 months. However, both groups of DP
patients displayed significant increases in FPG and HbA1c
levels within 3 months following surgery, but without fur-
ther increases thereafter. These data lead us to hypothesize
that, while surgical reduction of pancreatic parenchyma
volume quickly impairs glucose metabolism, the observed
lag in diabetes onset depends on other factors, such as the
amount and overall health of the remaining endocrine pan-
creas that control plasma glucose.
In patients with insufficient functional reserve of the
remnant pancreas to compensate for beta cell deficit (with
severity depending on the volume of the pancreas removed),
overt diabetes would develop in the early postoperative
period (within 3 months postoperatively). The functional
reserve of the endocrine pancreas could be estimated based
on the preoperative HbA1c value, which was identified as a
risk factor predictive of postoperative diabetes in this study.
In patients with late-onset diabetes (later than 3 months after
surgery), beta cell compensation would considerably influ-
ence the diabetes onset time. In the field of islet cell trans-
plants, although obese individuals are generally at high risk
of diabetes, it has been reported that the high demand for
insulin in obese donors without diabetes promotes the nec-
essary increase in islet cell hypertrophy and proliferation.24
Islet cells that remain after pancreatectomy are likely in a
similar situation that stimulates islet hypertrophy and thus a
compensatory increase in insulin secretion in the endocrine
pancreas. Eventually, however, this pre-diabetic state may
progress to overt diabetes once the endocrine pancreas is
exhausted and fails to control glucose homeostasis. Also,
Table 4 Univariate analysis of
risk factors for postoperative
new-onset diabetes
Values are means±SE, medians
(range) or n (%)
HbA1c hemoglobin A1c, FPG
fasting plasma glucose, POPF
postoperative pancreatic fistula
ap values were obtained using
Fisher’s exact test
bp values were obtained using
Student’s t test








Male patients 9 (41) 15 (38) 1.00a
Age (years) 67±3.0 59±2.2 0.025b
BMI (kg/m2) 22±0.78 20±0.59 0.075b
Preoperative HbA1c≥5.7 % 18 (82) 14 (36) 0.001a
Preoperative IFG 6 (27) 3 (8) 0.059a
Preoperative albumin (mg/dl) 3.9±0.13 4.0±0.10 0.59b
Preoperative total cholesterol (mg/dl) 176±9.6 186±7.3 0.42b
Preoperative pancreatic alpha-amylase (IU/l) 58 (6–243) 59 (4–264) 0.98c
Operative time (min) 312±19 347±15 0.14b
Intraoperative blood loss (ml) 372 (5–1125) 527 (5–3524) 0.17c
Malignancy 8 (36) 17 (44) 0.79a
PRV>44 % 15 (75) 6 (19) <0.001a
POPF ≥ grade B 6 (27) 10 (26) 1.00a
Postoperative complication ≥ Clavien’s grade II 7 (32) 15 (38) 0.78a
Postoperative hospital stay (days) 16 (7–54) 18 (7–58) 0.60c
Adjuvant chemotherapy 7 (32) 15 (38) 0.78a
Table 5 Multivariate logistic regression analysis of risk factors
for postoperative new-onset diabetes
Odds ratio 95 % CI p value
Age 1.03a 0.96–1.11 0.42
Preoperative IFG 1.52 0.18–14.7 0.69
Preoperative HbA1c≥5.7 % 15.6 2.80–147 0.001
PRV>44 % 11.3 2.12–92.1 0.004
a Odds ratio by 1 year post-DP
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additional factors that vary the timing of late-onset postop-
erative diabetes include normal progression of underlying
diseases, such as pancreatitis, as well as acquired risk factors
for type 2 diabetes (e.g., weight gain or aging).
Our analyses identified preoperative HbA1c as a second
risk factor for postoperative new-onset diabetes. HbA1c is
increasingly viewed as a superior index of chronic hyper-
glycemia relative to plasma glucose (which varies during the
day), and the American Diabetes Association recently added
HbA1c≥6.5 % to its diagnostic criteria for the detection of
early diabetes, with slightly lower HbA1c values (from 5.7
to 6.4 %) categorized as signaling an increased risk of
diabetes.1 In our study, the cutoff value at which HbA1c
became a risk factor was 5.7 %. Among the study’s 61
patients (none of whom met the WHO criteria for diabetes,
FPG≥126 mg/dl), preoperative HbA1c was ≥6.5 % in two
patients and between 5.7 and 6.4 % in another 30 patients.
Of these 32 individuals, 18 patients (56 %) developed post-
operative diabetes. However, it is noteworthy that four ad-
ditional patients with HbA1c<5.7 %, but relatively high
PRV (from 47 to 61 %), also developed diabetes.
The metabolic consequences of pancreatic resection are
multifaceted and can be affected by glucoregulatory hor-
mone concentrations, the balance between production and
utilization of glucose, changes in insulin sensitivity and
nutritional status, surgical complications,25,26 and tumor
character (malignant or benign). Despite decreases in insulin
secretion, some studies have reported post-pancreatectomy
improvements in glucose control in malignant cases.27,28
Because malignant pancreatic tumors are known to produce
substances that impair the action of insulin and decrease
insulin sensitivity, a patient’s diabetic status can sometimes
improve after tumor removal.29,30 Of the nine patients in our
study who showed stable glycemic control (eight with
HbA1c≤0.1 %) or improved control (one with HbA1c re-
duced by 0.4 %) during the post-DP follow-up period, five
had malignant tumors. The one patient with improved gly-
cemic control had a highly advanced cancer, as well as
preoperative HbA1c and BMI levels of 6.2 % and 28.7 kg/
mm2, respectively, indicating pre-diabetes. This patient lost
13 % of his body weight within 3 months after surgery, and
it is likely that this loss helped suppress the progression of
type 2 diabetes. Our results did not demonstrate any influ-
ence of malignant tumors on postoperative endocrine
function.
Conclusion
Adequate preoperative functional reserve of the endocrine
pancreas (HbA1c<5.7 %) and maximizing the volume of
the pancreatic parenchyma preserved are two key determi-
nants of successful postoperative glycemic control. Our
findings enable reliable preoperative evaluation of the risk
of developing diabetes and to perform postoperative surveil-
lance appropriately. Late-onset diabetes needs to be recog-
nized as a common sequela of DP, and longitudinal follow-
up and preventive intervention (weight control and anti-
diabetic agents for pre-diabetic patients) should be intro-
duced in high-risk patients.
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